News

The European Commission is planning to define standard information requirements (REACH Annexes VII-X) to evaluate possible endocrine effects of chemicals registered under the REACH Regulation. Furthermore, a change of REACH Annex I is proposed to include an assessment of endocrine disruption as a separate entity (much like the assessment of PBT/vPvB properties that is already required). As a consequence, the Chemical Safety Report will be extended as well and the plans envisage that ECHA develops a corresponding Guidance Document.  While details of the standard information requirements are yet to be drafted, the work required for a chemical safety assessment is likely to increase substantially in the future.

Two webinars will be held in early November (see dates and times below). The webinars will focus on the ADCR, and its activities. In particular, the webinars will give participants the chance to ask any questions they may have and to raise any issues they are encountering in terms of the chromates authorisations. All Aerospace and Defence stakeholders are welcome to register by clicking on a date and time below.
Dates and times:
5 Nov 1600-1700 (CET)
6 Nov 1600-1700 (CET)

Melany Macherey was invited to the annual meeting of the German Association for Waste Oil (Bundesverband Altöl e.V., BVA), which was held on 19 and 20 September in Potsdam. She presented the results of the evaluation report on the classification of waste oils according to the CLP Regulation in the context of the assessment of wastes according to the accident prevention regulation, which FoBiG prepared on behalf of the BVA. The background of the report is the working aid for the classification of waste under Annex I of the 12th BImSchV ("NRW-Leitfaden"), which was published in summer 2018 and according to which waste oils are to be classified as environmentally hazardous substances pursuant to category E2 of Annex I of the 12th BImschV. The evaluation report assesses the relevance of contaminants in representative samples for the classification of oil mixtures.

Please contact Melanie Macherey for further information.

Due to their material properties, epoxy resins are used in many industries. While cured epoxy resins are dermally non-hazardous, ingredients of the starting components may have sensitizing properties that can lead to allergic skin reactions.. In the past, FoBiG was involved in two DGUV funded projects to assess the sensitizing potency of epoxy resin ingredients (FP-0324 and FP-0384, Heine et al. 2012, 2016). In order to supplement the work of the existing two research projects, the working group “Epoxy Resin Ingredients” (AK EIS) was founded in 2017 in addition to the existing working group “Epoxy Resins”. FoBiG scientifically supports the AK EIS. For example, a calculator, the “EIS-Gemischerechner”, was developed. It is a practical tool that compares two technically exchangeable epoxy resin products with regard to their sensitizing potency. The results of the extensive work of both working groups and the research projects is now available online on the updated epoxy resin page of the Federal Institute for Occupational Safety and Health (German only).

For further information, please contact Karin Heine.

Melanie Macherey and Markus Schwarz attended this year's conference of the Society of Environmental Toxicology and Chemistry (SETAC) Europe in Helsinki (26-30 May). Again this year, endocrine disruption was an important issue, also on account of the new "ECHA/EFSA Guidance for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009", published in June 2018. In order to meet the requirements of the Guidance, concepts were discussed and new scientific methods were presented, e.g. for modelling population-relevant adverse effects in non-target organisms or for identifying endocrine disruption of thyroid hormone signaling. There was also a lively discussion as to whether - in view of a hazard-based assessment in the EU - biological plausibility alone is sufficient, or whether the causality of the link is decisive if an adverse effect is to be assigned to a specific endocrine mechanism of action; and what role the mechanistic potency of a substance plays for this mechanism of action.